Estrella Immunopharma Inc. (NASDAQ:ESLA) saw its stock rise 3.1% in premarket trading Thursday after announcing that its CD19-directed cancer therapy has been cleared to move into Phase II clinical testing.

The biopharmaceutical company said an independent Data Safety Monitoring Board (DSMB) endorsed advancing the STARLIGHT-1 study into its expansion phase following a positive safety evaluation of EB103, the firm’s treatment for relapsed or refractory B-cell non-Hodgkin’s lymphoma.

Estrella reported that the Phase I dose-escalation stage showed no treatment-related serious adverse events among nine patients — several of whom were classified as high-risk. In the highest dose group, all evaluable participants achieved a complete response at the one-month mark.

“The advancement of EB103 into the expansion phase of STARLIGHT-1 is a pivotal milestone for Estrella,” said Cheng Liu, CEO of Estrella Immunopharma. “The excellent safety profile and a 100% complete response rate observed in the high-dose cohort in Phase I demonstrated EB103’s potential to overcome the toxicity barriers that have historically restricted CD19 CAR-T use.”

EB103 is a CD19-redirected ARTEMIS T-cell therapy intended for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The upcoming expansion phase will further assess safety and early signs of efficacy at the Recommended Phase II Dose.

The open-label, multi-center trial is being conducted at several locations, including UC Davis Comprehensive Cancer Center and the Baylor Scott & White Research Institute.

Estrella Immunopharma stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.